Evogene (EVGN) Competitors $1.20 +0.01 (+0.42%) Closing price 03:55 PM EasternExtended Trading$1.25 +0.04 (+3.32%) As of 05:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EVGN vs. CARM, SNES, TOMZ, ENFY, GURE, NITO, BSLK, CNEY, TANH, and GAMCWShould you be buying Evogene stock or one of its competitors? The main competitors of Evogene include Carisma Therapeutics (CARM), Senestech (SNES), TOMI Environmental Solutions (TOMZ), Enlightify (ENFY), Gulf Resources (GURE), N2OFF (NITO), Bolt Projects (BSLK), CN Energy Group. (CNEY), Tantech (TANH), and Golden Arrow Merger (GAMCW). Evogene vs. Its Competitors Carisma Therapeutics Senestech TOMI Environmental Solutions Enlightify Gulf Resources N2OFF Bolt Projects CN Energy Group. Tantech Golden Arrow Merger Carisma Therapeutics (NASDAQ:CARM) and Evogene (NASDAQ:EVGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, risk and dividends. Does the media prefer CARM or EVGN? In the previous week, Carisma Therapeutics had 1 more articles in the media than Evogene. MarketBeat recorded 2 mentions for Carisma Therapeutics and 1 mentions for Evogene. Evogene's average media sentiment score of 0.97 beat Carisma Therapeutics' score of 0.30 indicating that Evogene is being referred to more favorably in the news media. Company Overall Sentiment Carisma Therapeutics Neutral Evogene Positive Do insiders & institutionals hold more shares of CARM or EVGN? 44.3% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 10.4% of Evogene shares are held by institutional investors. 6.9% of Carisma Therapeutics shares are held by insiders. Comparatively, 7.4% of Evogene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has preferable earnings and valuation, CARM or EVGN? Evogene has lower revenue, but higher earnings than Carisma Therapeutics. Evogene is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCarisma Therapeutics$19.63M0.67-$60.48M-$1.56-0.20Evogene$8.51M0.76-$16.49M-$2.25-0.54 Which has more risk and volatility, CARM or EVGN? Carisma Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Evogene has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Do analysts recommend CARM or EVGN? Carisma Therapeutics presently has a consensus price target of $1.93, suggesting a potential upside of 512.67%. Evogene has a consensus price target of $3.50, suggesting a potential upside of 190.46%. Given Carisma Therapeutics' higher probable upside, analysts plainly believe Carisma Therapeutics is more favorable than Evogene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Carisma Therapeutics 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 2.71Evogene 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is CARM or EVGN more profitable? Evogene has a net margin of -211.61% compared to Carisma Therapeutics' net margin of -254.28%. Carisma Therapeutics' return on equity of 0.00% beat Evogene's return on equity.Company Net Margins Return on Equity Return on Assets Carisma Therapeutics-254.28% N/A -192.17% Evogene -211.61%-109.96%-38.47% SummaryCarisma Therapeutics beats Evogene on 9 of the 16 factors compared between the two stocks. Get Evogene News Delivered to You Automatically Sign up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVGN vs. The Competition Export to ExcelMetricEvogeneMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.47M$3.13B$5.73B$10.28BDividend YieldN/A2.36%5.88%4.63%P/E Ratio-0.5421.1776.7426.53Price / Sales0.76452.17526.07121.12Price / CashN/A45.4037.2060.52Price / Book0.449.5613.946.31Net Income-$16.49M-$53.02M$3.29B$271.37M7 Day Performance-6.08%0.37%0.63%2.11%1 Month Performance-10.74%3.93%4.32%6.67%1 Year Performance-57.57%8.61%84.13%27.84% Evogene Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVGNEvogene2.8936 of 5 stars$1.21+0.4%$3.50+190.5%-60.0%$6.47M$8.51M-0.54140Short Interest ↓Gap UpCARMCarisma Therapeutics2.611 of 5 stars$0.36-10.6%$1.93+442.3%-66.7%$14.50M$19.63M-0.2220News CoverageShort Interest ↑SNESSenestech2.8528 of 5 stars$5.06+0.7%$10.00+97.8%+61.6%$24.95M$1.86M-0.9330News CoverageShort Interest ↓TOMZTOMI Environmental Solutions3.0841 of 5 stars$0.83-5.7%$3.50+321.2%+9.6%$16.69M$7.74M-3.6120News CoveragePositive NewsGap UpENFYEnlightify0.3338 of 5 stars$0.98-4.7%N/AN/A$15.48M$95.85M-0.79424Gap DownGUREGulf Resources1.1119 of 5 stars$0.77+2.7%N/A-28.6%$10.28M$7.66M-0.31420Short Interest ↓Gap UpNITON2OFF1.5617 of 5 stars$0.22+0.5%N/A-34.7%$7.67M$210K0.002Positive NewsBSLKBolt Projects0.593 of 5 stars$3.61-3.4%N/A-83.6%$7.55M$1.37M-1.4112Positive NewsGap DownCNEYCN Energy Group.1.0964 of 5 stars$2.00-10.8%N/A-81.3%$6.27M$50.96M0.00160Short Interest ↓High Trading VolumeTANHTantech1.2765 of 5 stars$2.05+0.3%N/A-63.5%$178K$42.94M0.0070Negative NewsGap DownGAMCWGolden Arrow MergerN/A$0.05+12.3%N/A-81.4%$0.00N/A0.0012Gap Up Related Companies and Tools Related Companies CARM Competitors SNES Competitors TOMZ Competitors ENFY Competitors GURE Competitors NITO Competitors BSLK Competitors CNEY Competitors TANH Competitors GAMCW Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVGN) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evogene Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evogene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
